Autolus Reports Strong Revenue Growth but Remains Unprofitable
Autolus Therapeutics (NASDAQ:AUTL) reported strong second-quarter results in August 2026 with net product revenue reaching $45.7 million, up from $20.9 million a year earlier and $26.2 million the previous quarter. The growth was driven by AUCATZYL, its CD19-directed CAR T therapy for adult relapsed or refractory B-cell precursor ALL, which saw increased demand in existing treatment centers and new UK availability. Despite this progress, Autolus still posted a net loss of $39.1 million for the quarter due to rising operational costs. The company raised its full-year revenue guidance to between $140 million and $150 million from a previous range of $120 million to $135 million. A five-year credit facility with Perceptive Advisors provided up to $250 million in funding, extending Autolus's cash runway through Q2 2028. However, the company’s cash reserves decreased during the quarter and it remains unprofitable. AUCATZYL carries significant safety warnings for cytokine release syndrome and neurologic toxicities observed in clinical trials. Additionally, $150 million of its new financing is contingent on hitting revenue milestones.
